<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04968834</url>
  </required_header>
  <id_info>
    <org_study_id>20-302</org_study_id>
    <nct_id>NCT04968834</nct_id>
  </id_info>
  <brief_title>Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy</brief_title>
  <official_title>Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charles H. Hood Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is a genomic profiling and repository study for children and young adults&#xD;
      who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes&#xD;
      are the part of cells that contain the instructions which tell cells how to make the right&#xD;
      proteins to grow and work. Genes are composed of DNA letters that spell out these&#xD;
      instructions. Genomic profiling helps investigators understand why the disease develops and&#xD;
      the instructions that led to its development. Understanding the genetic factors of the&#xD;
      disease can also help investigator understand why the disease of some people can respond to&#xD;
      certain therapies differently than others.&#xD;
&#xD;
      The genomic profiling will be performed using bone marrow and blood samples that either have&#xD;
      already been obtained during a previous clinical procedure or will be obtained at the time of&#xD;
      a scheduled clinical procedure. Studying the genetic information in the cells of these&#xD;
      samples will provide information about the origin, progression, and treatment of leukemia and&#xD;
      myeloproliferative syndromes and myelodysplastic syndrome. Storing the bone marrow and blood&#xD;
      samples will allow for additional research and genomic assessments to be performed in the&#xD;
      future.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pediatric patients with new diagnosis or relapsed/refractory acute leukemia, MDS/AML, chronic&#xD;
      leukemia, myeloproliferative syndromes or myelodysplastic syndrome will be enrolled onto this&#xD;
      study. At the time of enrollment, a sample of the leukemia will be submitted for genomic&#xD;
      profiling using CLIA assay(s). This information will be returned to the treating oncologist.&#xD;
      The study will collect follow up data on patient outcome and whether the genomic profiling&#xD;
      influenced treatment.&#xD;
&#xD;
      It is expected that about 100 people each year will take part in this research study at 8&#xD;
      medical centers in the United States&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2021</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Number of Patients Enrolled for Genomic Profiling-Pediatric Leukemia</measure>
    <time_frame>3 Years</time_frame>
    <description>To perform genomic profiling of pediatric leukemia using clinical genomics platforms and return results to treating oncologist. This objective will be accomplished by enrolling patients and obtaining samples for sequencing and banking. The pathologist-interpreted genomic test results will be returned to the treating oncologist.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Enrolled for Genomic Profiling-New Diagnosis</measure>
    <time_frame>3 Years</time_frame>
    <description>To collect and bank samples from pediatric patients with new diagnosis or relapsed/refractory acute and chronic leukemia, and myelodysplastic syndrome. This objective will be accomplished by enrolling patients and obtaining samples for sequencing and banking.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myeloproliferative Syndrome</condition>
  <arm_group>
    <arm_group_label>GENOMIC PROFILING AND SPECIMEN BANKING REGISTRATION ARM</arm_group_label>
    <description>The research study procedures include screening for eligibility, reviewing and signing this consent form, collecting patient information and clinical data, obtaining previously collected bone marrow and blood samples, and completing a brief optional Household Survey. Bone marrow and blood samples may also be collected in the future as part of your routine clinical procedures</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genomic profiling</intervention_name>
    <description>Genomic profiling using CLIA assay</description>
    <arm_group_label>GENOMIC PROFILING AND SPECIMEN BANKING REGISTRATION ARM</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        - birth to &lt; 30 years of age. Patient with acute leukemia, chronic leukemia, MDS/AML,&#xD;
        myelodysplastic syndrome or myeloproliferative syndromes. Disease can be newly diagnosed or&#xD;
        relapsed/refractory.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: birth to &lt; 30 years of age&#xD;
&#xD;
          -  Diagnosis:&#xD;
&#xD;
             -- Patient with acute leukemia, chronic leukemia, MDS/AML, myelodysplastic syndrome or&#xD;
             myeloproliferative syndromes. Disease can be newly diagnosed or relapsed/refractory.&#xD;
&#xD;
          -  Pathology Criteria:&#xD;
&#xD;
             -- Histologic confirmation of leukemia or myelodysplastic syndrome (MDS) or&#xD;
             myeloproliferative syndrome (MPS) at the time of diagnosis or recurrence&#xD;
&#xD;
          -  Specimen Criteria:&#xD;
&#xD;
               -  Sufficient sample available for genomic profiling OR bone marrow aspirate/blood&#xD;
                  draw planned for clinical care which is anticipated to allow collection of&#xD;
                  minimum specimen for testing (See Section 6.1 for description of specimen&#xD;
                  requirements)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Insufficient leukemia or MDS specimen available for profiling from diagnosis or&#xD;
        recurrence (See Section 6.1); or bone marrow evaluations NOT planned for clinical care; or&#xD;
        peripheral blast percentage &lt;20%, or clinical blood draw not planned&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yana Pikman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yana Pikman, MD</last_name>
    <phone>(617) 632-4754</phone>
    <email>yana_pikman@dfci.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Childrens Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yana Pikman, MD</last_name>
      <phone>617-632-4754</phone>
      <email>yana_pikman@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Yana Pikman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jessica Pollard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yana Pikman, MD</last_name>
      <phone>617-632-4754</phone>
      <email>YPIKMAN@PARTNERS.ORG</email>
    </contact>
    <investigator>
      <last_name>Yana Pikman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jessica Pollard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bonnie Lau, MD</last_name>
      <phone>603-650-5000</phone>
    </contact>
    <investigator>
      <last_name>Bonnie Lau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 9, 2021</study_first_submitted>
  <study_first_submitted_qc>July 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2021</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Yana Pikman, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>Myeloproliferative syndrome (MPS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data can be shared no earlier than 1 year following the date of publication</ipd_time_frame>
    <ipd_access_criteria>Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

